Expression of the labeled recombinant glycoprotein E2 of the classical swine fever virus in E. Coli

Currently, live attenuated vaccines are used in the Russian Federation for the specific prevention of classical swine fever (CSF), but this strategy contradicts the rules for importing animal products and carries the risks of recombination with field strains. These factors exacerbate the need for further development of candidate recombinant vaccines with similar efficacy and safety. The aim of the presented work was to construct a prokaryotic expression system of the marked glycoprotein E2 of the CSF virus and to evaluate its immunochemical properties. As a result of the conducted studies, a section of the primary amino acid sequence of glycoprotein E2 of a highly pathogenic Shimen strain (subgenotype 1.1) was identified using bioinformatic analysis and a hybrid polypeptide was designed, including a non-specific (marker) part from the modified V5 epitope and a fragment of the BSA sequence. By cloning a codon-optimized fragment into the pET-28a vector, the E. coli BL21(DE3) pLysS/pET-28a/E2-V5 producing strain was constructed. During the optimization of the cultivation conditions of the producer strain, it was found that the highest yield of the target protein is achieved within 5-6 hours after the induction of expression. The immunochemical properties of chromatographically purified recombinant rE2-V5 were determined: for example, it was shown that its activity in indirect enzyme immunoassay exceeds that of native E2. The data obtained indicate the effectiveness of the developed prokaryotic expression system, which consists in proper folding, good solubility and the ability of the target protein to form specific immunocomplexes. The presence of a marker fragment in the expressed hybrid polypeptide in the future will allow using the latter as the basis of a recombinant vaccine that meets the requirements of the DIVA strategy.

1. Alekseev K.P., Raev S.A., Yuzhakov A.V., Shemelkov E.V., Latyshev O.E., Eliseeva O.V., Kostina L.V., Tsibezov V.V., Stafford V.V., Kunakov V.Yu., Verkhovsky O.A., Zaberezhny A.D., Aliper T.I. Development and testing of recombinant subunit vaccine samples against the classic swine fever. Agricultural biology. 2019; 54(6): 1236-1246. DOI: 10.15389/agrobiology.2019.6.1236rus.

2. Sergeev V.A., Orlyankin B.G., Alekseev K.P., Zaberezhny A.D., Aliper T.I., Nepoklonov E.A. Vaccines and vaccination strategy against classical swine fever. Veterinary medicine. 2018; 4: 3-11.

3. Oganesyan A.S., Shevtsov A.A., Shcherbakov A.V., Korennoy F.I., Karaulov A.K. Classical swine fever: a retrospective analysis of the epizootic situation in the Russian Federation (2007-2021) and forecast for 2022. Veterinary medicine today. 2022; 11 (3): 229-238. DOI: 10.29326/2304-196X-2022-11-3-229-238.

4. Shemelkov E.V., Bulgakov A.D., Kulikova T.S., Verkhovsky O.A., Kunakov V.Yu., Kotelnikov A.P., Aliper T.I. Study of the duration of the post-vaccination immune response when using a subunit labeled vaccine against classical swine fever. Agricultural science. 2022; 3: 23-27. DOI: 10.32634/0869-8155-2022-357-3-23-27.

5. Aliper T.I., Alekseev K.P., Shemelkov E.V., Verkhovsky O.A., Zaberezhny A.D. The prospect of using labeled vaccines against classical swine fever in the Russian Federation. Scientific foundations of the production and quality assurance of biological preparations: materials of the IPC dedicated to the 100th anniversary of the Armavir Biofactory. 2021. 54-60. DOI: 10.47804/978-5-89904-028-3_2021_ 54.

6. Wang F., Yu Q., Hu M., Xing G., Zhao D., Zhang G. Purification of Classical Swine Fever Virus E2 Subunit Vaccines Based on High Affinity Peptide Ligand. Protein Pept Lett. 2021; 28(5):554-562. DOI: 10.2174/0929866527666201103152100.

7. Kumar R., Kumar V., Kekungu P., Barman N.N., Kumar S. Evaluation of surface glycoproteins of classical swine fever virus as immunogens and reagents for serological diagnosis of infections in pigs: a recombinant Newcastle disease virus approach. Arch Virol. 2019; 164: 3007-3017. DOI: 10.1007/s00705-019-04425-4.

8. Nakane P.K., Kawaoi A. Peroxidaselabeled antibody: a new method of conjugation. J. Histochem. Cytochem. 1974; 22(12). DOI: 10.1177/22.12.1084.

9. Patent RU2250263C1. Andreev V.G., Bezborodova S.V. Recombinant plasmid DNA p30NE2 encoding the 181-amino acid N-terminal fragment of glycoprotein E2 of the classical swine fever virus and ensuring its expression in E. coli cells. The applicant and the patent holder is the Federal State Institution «ARRIAH». Date of publication – 27.01.2005.

10. Patent RU2406534C2. Toledo Alonso H.R., Sanchez Ramos O., Barrera Valle M.I., Figueroa Baile N.E., Prieto Carratala Ya., Rodriguez Molto M.P., Frias Lepuro M.T., Borroto Nordelo K.G. Chimeric vaccine antigens against classical swine fever virus. The applicant and the patent holder is Centro de Ingeneria Henetika i Bioteknolohija (CU). Date of publication – 07.09.2007.

11. Patent EP2382307B1. Kortekaas J.A., Vloet R.P.M. Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV. Current Assignee: Intervet International BV. Publication date: 02.11.2011.

12. Wei Q., Liu Yu., Zhang G. Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus. Viruses. 2021; 13(3): 445. DOI: 10.3390/v13030445.

13. Kimple M. E., Brill A. L., Pasker R. L. Overview of affinity tags for protein purification. Curr Protoc Protein Sci. 2013; 73(9).